An Open Label, Multicenter Study, Evaluating the Safety and Efficacy of 18F-AV-133 PET Imaging to Identify Subjects With Dopaminergic Degeneration Among Subjects Presenting to a Movement Disorders Specialty Clinic With an Uncertain Diagnosis
Phase of Trial: Phase II/III
Latest Information Update: 14 Feb 2017
Price : $35 *
At a glance
- Drugs Florbenazine F18 (Primary)
- Indications Parkinsonian disorders
- Focus Diagnostic use
- Sponsors Avid Radiopharmaceuticals
- 30 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 05 Aug 2014 New trial record